Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)

• Status: Suspended
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sclnow Biotechnology Co., Ltd.
• Treatments: Azacitidine; Decitabine

Criteria

Inclusion Criteria:

• MDS patients with international prostate symptom score is moderate or severe symptoms

Exclusion Criteria:

• with serious renal function impaired

• with other organ function abnormal: acute hepatitis B, ejection fraction < 40%, serum bilirubin > 3mg/dl, liver function tests abnormal, central nervous system disease, mental disease

• bad physical condition (Karmofsky < 60%)

• without signing informed consent form

• under other therapy that possibly influence MSC security or efficacy

• HIV or other serious disease infection

• Donor: HIV, active hepatitis B/C infection, Syphilitic antibody positive

• Donor/ participants: alcoholism, drug addicted, mental disease